Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer

European Journal of Cancer(2022)

Cited 12|Views4
No score
Abstract
Image 1
More
Translated text
Key words
CDK4/6 inhibitor,Neoadjuvant,Luminal breast cancer,Chemotherapy,Survival
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined